Navigation Links
Ipsen Biopharmaceuticals Joins National Pharmaceutical Council
Date:3/28/2017

WASHINGTON, March 28, 2017 /PRNewswire-USNewswire/ -- The National Pharmaceutical Council (NPC) today announced that Ipsen Biopharmaceuticals, Inc. has joined the health policy research organization as its newest member. David Cox, PhD, Vice President, Medical and Regulatory Affairs (North America), will serve as his company's representative on NPC's Board of Directors.

"We're pleased to have Ipsen and Dr. Cox join NPC as members," said NPC President Dan Leonard. "We welcome their insights in helping us identify and address health care priorities in today's rapidly changing policy environment."

Ipsen Biopharmaceuticals, Inc. is the U.S. affiliate of Ipsen, a global specialty-driven pharmaceutical group focused on discovering, developing and commercializing new therapeutic options for oncologic, neurologic and endocrine diseases.

"At a time when all of us in health care are facing a number of challenges, we appreciate NPC's thoughtful, research-oriented approach in considering how to improve health system efficiencies and lower access barriers to high-value care, among other issues," said Dr. Cox. "We're looking forward to engaging with NPC on these important health care matters."

About the National Pharmaceutical Council
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation's major research-based pharmaceutical companies, NPC focuses on research development, information dissemination and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit www.npcnow.org and follow NPC on Twitter @npcnow.

About Ipsen in North America
Ipsen Biopharmaceuticals, Inc. is the U.S. affiliate of Ipsen, a global specialty-driven pharmaceutical group. The U.S. head office is located in Basking Ridge, New Jersey. Ipsen Biopharmaceuticals Canada, Inc. is an integrated business unit within North America and has its head office located in Mississauga, Ontario. Ipsen Bioscience, Inc., the Ipsen U.S. research and development center focused on peptide research in oncology and endocrinology, is located in Cambridge, Massachusetts. At Ipsen Bioscience, we focus on creating a highly cooperative and passionate R&D organization through partnerships, innovation, and continuous learning to effectively deliver new treatments for patients. At Ipsen, we focus our resources, investments, and energy on discovering, developing, and commercializing new therapeutic options for oncologic, neurologic, and endocrine diseases. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ipsen-biopharmaceuticals-joins-national-pharmaceutical-council-300429896.html


'/>"/>
SOURCE National Pharmaceutical Council
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. New 62,600 Square Foot Lease At 650 East Kendall Street Signed By Ipsen And BioMed Realty
2. Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
3. Ipsen and EpiVax collaborate to produce next generation botulinum toxins
4. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
5. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
6. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
7. PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
8. Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
9. Before the Bell Scans: Hologic Inc., St. Jude Medical Inc., ResMed Inc., and Navidea Biopharmaceuticals Inc.
10. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
11. Biopharmaceuticals - A Global Market Overview
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2020)... , ... January 24, 2020 , ... ... created by companies in biotechnology, diagnostics, therapeutics, laboratory and clinical services during the ... of people around the world. And as Slone Partners celebrates its ...
(Date:1/22/2020)... ... January 20, 2020 , ... Brilliant, maker of the award-winning ... independent electronics distributor in the US, to make it easy for homebuilders, multifamily ... smart home products from a single fulfillment partner. Ranging from entry-level systems for ...
(Date:1/22/2020)... , ... January 21, 2020 , ... QCDx , ... biopsy from a simple blood draw, today announced the sale of the proprietary RareScope™ ... Rare Scope will be used in clinical cancer research. , “The RareScope can detect ...
(Date:1/10/2020)... ... January 09, 2020 , ... ... announced its inaugural GenScript Biotech Global Forum on Jan. 14 in San Francisco, ... "Cell and Gene Therapy and the Booming China Market," will feature gene and ...
Breaking Biology Technology:
(Date:2/13/2020)... ... February 13, 2020 , ... Murrieta Genomics , the provider ... a lunch and learn event on February 25th from 11:30 am to 1 pm ... members of the public are invited to attend this free event, but must ...
(Date:2/13/2020)... (PRWEB) , ... February 13, 2020 , ... ... announce an exclusive interview with Nobio CEO Yoram Ashery to discuss ... Nobio is a company that combats bacteria to keep people healthy with their ...
(Date:2/11/2020)... ... , ... The LaunchPort™ announced today that ExoRenal ( http://www.exorenal.com ... The newly formed company is developing a novel pulsatile hemodialysis technology that is ... dialysis treatments. The start-up company will be moving research functions from New England ...
Breaking Biology News(10 mins):